Clinical Trials · NCT05352815
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,291
- Start date
- Jun 2022
- Locations
- 281 sites, 22 countries
- Primary endpoint
- Change in Glycated Haemoglobin (HbA1c)